List of Doptelet drug patents
Doptelet is owned by Akarx Inc.
Doptelet contains Avatrombopag Maleate.
Doptelet has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Doptelet are:
- US8765764
Doptelet was authorised for market use on 21 May, 2018.
Doptelet is available in tablet;oral dosage forms.
Doptelet can be used as treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure, treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment.
Drug patent challenges can be filed against Doptelet from 2022-05-21.
The generics of Doptelet are possible to be released after 26 June, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
May, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765764 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jan, 2023
(2 months ago) | |
| US8338429 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jun, 2023
(2 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 21, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 26, 2026 |
Drugs and Companies using AVATROMBOPAG MALEATE ingredient
NCE-1 date: 2022-05-21
Market Authorisation Date: 21 May, 2018
Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; Treatment of thrombocytopenia in an adult patient with chronic live...
Dosage: TABLET;ORAL
DOPTELET family patents
5
Japan
4
United States
2
Spain
2
European Union
1
Luxembourg
1
Belgium
1
Hungary
1
Slovenia
1
Portugal
1
Denmark
1
Cyprus
1
Canada
1
Netherlands
1
Korea, Republic of
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic